NCT05068336

Brief Summary

The glycocalyx is a dynamic and complex biochemical structure composed of proteoglycans, glycoproteins, and soluble proteins. The glycocalyx interacts with various proteins such as albumin and orosomucoid to form a thick surface layer on the vessel surface that is physiologically active. This is called the endothelial surface layer. This structure is constantly changing with the blood flowing in the vein. The glycocalyx regulates oncotic pressure and also prevents leukocyte and platelet adhesion to the endothelium. Endothelial cell dysfunction is a valuable marker of increased vascular permeability and impaired angiogenesis due to cardiovascular, thoracic, renal, and metabolic diseases.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 20, 2021

Completed
5 days until next milestone

Study Start

First participant enrolled

August 25, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 5, 2021

Completed
20 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 25, 2021

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 4, 2021

Completed
Last Updated

November 9, 2021

Status Verified

November 1, 2021

Enrollment Period

2 months

First QC Date

August 20, 2021

Last Update Submit

November 6, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • glycocalyx components

    The primary aim of the study was to measure the levels of heparan sulfate and syndecan, which are markers of endothelial glycocalyx structure, after the use of desflurane or sevoflurane. High biomarker levels are associated with impaired glycocalyx structure

    the study will comlete in one month

Secondary Outcomes (1)

  • haemodynamic changes

    studdy will complete in one month

Study Arms (2)

desflurane

Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.

Diagnostic Test: desflurane anesthesia

sevoflurane

Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.

Diagnostic Test: sevoflurane anesthesia

Interventions

desflurane anesthesiaDIAGNOSTIC_TEST

Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.

desflurane
sevoflurane anesthesiaDIAGNOSTIC_TEST

Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.

sevoflurane

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

healthy volunteers

You may qualify if:

  • Be in the 18-65 age rang
  • Being in the ASA 1-3 risk group
  • patients receiving general anesthesia

You may not qualify if:

  • refuse to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tahsin Şimşek

Istanbul, Kartal, 34000, Turkey (Türkiye)

Location

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
medical doctor

Study Record Dates

First Submitted

August 20, 2021

First Posted

October 5, 2021

Study Start

August 25, 2021

Primary Completion

October 25, 2021

Study Completion

November 4, 2021

Last Updated

November 9, 2021

Record last verified: 2021-11

Locations